Insmed is a biopharmaceutical company based in Bridgewater, New Jersey, focusing on therapies for rare diseases, employing 912 staff. Its key products include ARIKAYCE, brensocatib, and TPIP for various lung diseases.
Insmed (INSM) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Insmed's actual EPS was -$1.70, missing the estimate of -$1.32 per share, resulting in a -28.87% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
